Mutations in BRCA1 and BRCA2 account for the majority of hereditary breast and ovarian 3 cancers, and therefore sequence analysis of both genes is routinely performed in patients 4 with early-onset breast cancer. Besides mutations that clearly abolish protein function or 5 are known to increase cancer risk, a large number of sequence variants of uncertain 6 significance (VUS) have been identified. Although several functional assays for BRCA1 7 VUS have been described, thus far it has not been possible to perform a high-throughput 8 analysis in the context of the full-length protein. We have developed a relatively fast and 9 easy cDNA-based functional assay to classify BRCA1 VUS based on their ability to 10 functionally complement BRCA1-deficient mouse embryonic stem cells. Using this assay 11
Introduction 1 2
Germline loss-of-function mutations in BRCA1 and BRCA2 are known to result in an 3 approximately 10-fold increased lifetime risk of developing breast or ovarian cancer. Thus 4 far, no other genes have been identified with such a strong link to hereditary breast and 5 ovarian cancer (HBOC) and during the past decades many women have been screened 6 for germline mutations in BRCA1 or BRCA2. This has resulted in the identification of 7 numerous pathogenic mutations as well as a large number of sequence variants of which 8 the clinical relevance is not clear. In the most recent publication of the ENIGMA group, an 9 international consortium for the evaluation of BRCA1 or BRCA2 sequence variants, a total 10 number of 1273 unique BRCA1 variants is mentioned (1) but this number may even 11 increase further because of the implementation of high-throughput sequencing methods. 12
Of the BRCA1 VUS, 920 are non-truncating exonic mutations that may affect protein 13 function or mRNA splicing, but for which there is not enough linkage information to indicate 14 whether they are pathogenic. To aid genetic counseling of individuals with BRCA1/2 VUS, 15 both genetic and functional classification methods have been developed. Genetic analysis 16 of BRCA1 or BRCA2 VUS relies on co-segregation with disease, co-occurrence with 17 known pathogenic mutations, and family history of cancer. These data have been 18 integrated into computational models to calculate the likelihood that a VUS is disease-19
Results

2
Generation of mouse embryonic stem cells expressing BRCA1 sequence variants 3
Although BRCA1-deficient tumor cells proliferate rapidly in situ, loss of BRCA1 in normal 4 cells leads to a severe proliferation defect (4). We decided to make use of this phenotype 5
for the functional analysis of BRCA1 variants in Brca1 selectable conditional knockout 6 (SCo) mouse ES cells (5) . These cells carry one Brca1-null allele and a selectable 7 conditional Brca1
SCo allele, which contains, in addition to loxP sites around exons 5-6, a 8 split puromycin resistance marker that is activated upon Cre-mediated deletion of exons 5-9 6. They also contain a CreERT2 allele in the Rosa26 locus, which allows for controlled 10 activation of Cre via administration of 4-hydroxy tamoxifen (4OHT). Thus, BRCA1-deficient 11
ES cells can be easily obtained via 4OHT-induced inactivation of the Brca1
SCo allele and 12 subsequent selection for puromycin resistance ( Fig. 1 
) (5). To allow efficient integration of 13
human BRCA1 variants in one specific genomic locus, we supplied the other Rosa26 allele 14 with F3 and Frt recombination sites for RMCE by the site-specific recombinase Flp ( Fig. 1  15 and Supplementary Fig. S1 ) (6). Cells that have undergone successful RMCE can be 16 selected because they express a truncated neomycin selection marker under control of the 17 endogenous Rosa26 promoter, which further increases targeting efficiency. Flp-mediated 18 recombination ensures single-copy integration of BRCA1 expression constructs at the 19 same Rosa26 locus, thus avoiding position-effect variegation and copy number-dependent 20 differences in expression. 21 RMCE vectors were equipped with a human BRCA1 cDNA expression construct, which 22 was modified using SDM to introduce defined mutations in BRCA1. The focus of our 23 analysis was on Dutch and Belgian VUS that were found in families with HBOC. We also 24 included a number of variants that were previously classified using functional assays (7, 8) or a multifactorial likelihood model (9), as well as M1400V, L1407P and M1411T, which 1 have been reported to attenuate the interaction between BRCA1 and PALB2 (10) . To allow 2 validation of our functional complementation assay, we included a series of 8 BRCA1 3 variants, which are known to be deleterious or neutral according to the Breast Cancer 4
Information Core database (BIC; http://research.nhgri.nih.gov/bic/; Supplementary Table  5 S1). These controls include the well-known pathogenic BRCA1 founder mutations 6 185delAG and 5382insC and the neutral polymorphisms Y105C, R866C and E1250K. The 7 BIC designation is supported by the classification according to the International Agency for 8
Research on Cancer (IARC; http://iarc.fr/), which includes the Align GVGD score that 9
indicates biophysical and evolutionary alterations (http://agvgd.iarc.fr/; Supplementary 10 Table S1 ) (11,12). Align GVGD scores vary between C0 (likely neutral) and C65 (likely 11 deleterious). Sequence verified constructs that contained the intended VUS, but no other 12 BRCA1 mutations, were transfected into R26 CreERT2/RMCE
;Brca1
SCo/ǻ ES cells to undergo 13 RMCE (Fig. 2) . Neomycin-resistant clones were pooled and RMCE was confirmed by 14 PCR analysis. Subsequently, protein expression of the human BRCA1 variants was 15 analyzed by western blot with a human BRCA1-specific antibody ( Fig. 2 and  16 
Supplementary Fig. S2). Comparison with BRCA1 protein levels in ES cells expressing 17
human BRCA1 from a bacterial artificial chromosome (BAC), which is known to rescue 18 embryonic lethality of Brca1-null mice (7, 13) , showed that transcription of the human 19 BRCA1 cDNA from the EF1A gene promoter results in physiological levels of BRCA1 20 protein ( Supplementary Fig. S1 ). Most BRCA1 mutants were expressed at equal levels, 21 allowing comparison of their functional activities. A number of C-terminal BRCA1 mutants 22
showed low levels of protein expression (Supplementary Table S2 , Supplementary Fig.  23 S2). RT-PCR analysis showed that decreased protein expression of these mutants was 24 not caused by decreased mRNA expression ( Supplementary Fig. S3 SCo/ǻ ES cells (Fig. 2) . Expression of 8 endogenous mouse Brca1 was shut-off through overnight induction of cre activity by 4OHT 9 and 7 days after switching cells were plated in 96-well plates for proliferation assays, 10 which were analyzed using Sulphorhodamine B staining. For each group of mutants 11 tested, we included positive and negative controls consisting of ES cells containing 12 respectively wild-type hBRCA1 cDNA and an empty RMCE vector. BRCA1 variants were 13 evaluated on their ability to support growth compared to these controls (Supplementary  14   Tables S3 and S4 ). Although we tested 28 mutations in the central domain encoded by 15 exon 11 (aa 224-1366), BRCA1 variants that were unable to rescue the proliferation defect 16 of Brca1-null mouse ES cells to BRCA1 wild-type levels were confined to the conserved N-17 and C-terminal domains of BRCA1. 18
19
Cisplatin sensitivity assay for classification of BRCA1 variants 20
While the ability of BRCA1 variants to support proliferation appears to be indicative of VUS 21 function, results were not always clear-cut (Supplementary Tables S3 and S4) . BRCA1 is 22 known to be important for DNA interstrand crosslink (ICL) repair through mechanisms that (10) -just C-terminal of the region encoded by exon 11 -had no effect on cisplatin 1 sensitivity in this assay. Of note, there was in general good correlation between our 2 classification and the Align GVGD score (Supplementary TableS4). Notable exceptions 3 are the neutral control variant R866C, which validates our assay but scores as likely 4 deleterious (C65) using Align GVGD, and G1770V, which is scored as likely neutral (C0) 5
by Align GVGD but classified as deleterious in our assay. Our assay also classifies some 6 variants for which the Align GVGD scores are less clear, emphasizing the usefulness of 7 functional assays to complement in silico analysis. 8
We also analyzed the possible effects of all BRCA1 variants on mRNA splicing, which may 9 have deleterious consequences but cannot be assessed in our cDNA based assay. Table S4 ). While c.5154G>T (encoding W1718C) is deleterious, three of 13 these variants are classified as neutral in our assay. One of them, c.441G>C (encoding 14 L147F) has an increased probability to damage the splice donor site of exon 7. Another 15 variant, c.5072C>T (encoding T1691I) might also affect splicing but no defect was 16 measured in blood samples of mutation carriers (19 transfected with a plasmid encoding the I-SceI meganuclease as well as an mCherry 8 fluorescent marker to control for transfection efficiency. Repair of I-SceI-induced DNA 9
DSBs in DR-GFP via HR leads to expression of GFP, which can be monitored by flow 10 cytometry. All but one predicted pathogenic variants tested resulted in defective HR, 11 thereby confirming our functional classification (Fig. 5) for olaparib than for cisplatin (Fig. 6) . However, this increase in dynamic range is 7 accompanied by an increased variation between repeat experiments for BRCA1-proficient 8 samples. Nevertheless, the functional defect of the R1699Q and V1736A mutations 9 becomes more evident, and there also appears to be a less than wild-type response for 10 the PALB2 interaction mutant L1407P. In the concurrent proliferation analysis, R1699Q 11 and V1736A both show an intermediate functional defect (Supplementary Fig. S4 ). Also 12 the M1411T mutation seems to affect the response to PARP inhibition but the difference 13 with BRCA1 wild-type is not significant. Interestingly, the L1407P and M1411T variants 14 have previously been shown to be more defective than M1400V in a gene conversion 15 assay (10) . It should be noted that, in contrast to the large-scale classification 16 experiments, also the cisplatin sensitivity assay performed in parallel to the PARP inhibitor 17 assay identified significant functional defects for L1407P and V1736A. 18
Discussion 1 2
Over the past few years several functional assays for classification of BRCA1 VUS have 3 been developed. Several of these assays are restricted to functions of the BRCA1 protein 4 that reside in the evolutionary conserved RING or BRCT domains. Examples include in 5 vitro transactivation assays for BRCT peptides (8) and measurement of ubiquitin ligase 6 activity for protein fragments encompassing the N-terminal RING domain (33). Other 7 assays were designed to evaluate the functions of full-length mutant BRCA1 protein, either 8 by monitoring general effects on proliferation or response to DNA damage (7) or by directly 9
focusing on the role of BRCA1 in DNA repair via HR (34). 10
Since BRCA1 VUS are not restricted to the N-or C-terminal domains -and given the 11 observation that interaction between these domains is required for recruitment of BRCA1 complementation of cells with these mutant constructs is time-consuming and technically 1 demanding, and can therefore not be performed in a high-throughput setting. We therefore 2 set out to develop a cDNA-based functional complementation assay in mouse ES cells 3 that is easier to control and scale-up and more suitable for routine functional classification 4 of BRCA1 sequence variants. 5
6
One advantage of BAC transgenics in complementation assays is that genes are 7 expressed at physiologically relevant levels. This is the result of low copy number 8 integrations and the presence of natural regulatory elements required for proper gene 9 expression. We decided to use RMCE to allow single-copy integration of BRCA1 cDNAs at 10 one specific genomic locus. The use of RMCE effectively prevents multiple or partial 11
integrations, concatemers and position-effect variegation. As a result, all variants are 12 expressed at equal levels. Moreover, transcription of BRCA1 cDNAs from the EF1A gene 13 promoter results in physiological levels of BRCA1 protein, comparable to those observed 14 in Brca1-null ES cells complemented with a BAC containing the human BRCA1 locus. 15
Indeed, the wild-type human BRCA1 cDNA was able to complement Brca1-null ES cells in 16 cellular proliferation, drug sensitivity and HR assays. Our RMCE strategy employs BRCA1 17 cDNA constructs in which mutations can be swiftly introduced using SDM, enabling a 18 higher throughput than introduction of mutations via BAC recombineering. In addition, the 19 introduction of BRCA1 cDNAs via RMCE obviates the need to analyze multiple ES cell 20 clones for correct integration and expression. reduced BRCA1 protein levels, most likely because of structural destabilization. In all 1 cases this led to diminished capacity for functional complementation. Also several variants 2 that gave rise to normal BRCA1 protein levels were unable to rescue the proliferation 3 defect and cisplatin sensitivity of Brca1-null ES cells. Since BRCA1 loss-of-function is 4 associated with increased cancer risk, variants that score as functionally impaired in our 5 ES cell assay system may be causally involved in tumor formation. This notion is 6 supported by the fact that 7 out of 8 known pathogenic or neutral control variants in our 7 validation series were correctly classified by the cisplatin sensitivity assay. The pathogenic 8 5382insC truncation mutation could not be classified because scored as neutral in 1 out of 9 3 transfection series. This was probably due to technical reasons, as the 5382insC 10 mutation did not restore HR activity in Brca1-deficient ES cells, in contrast to R1699Q, 11 which was recently shown to confer intermediate risk of HBOC (32). 12
13
Our assay system yielded ambivalent results for 9 other variants: S4F, S308A, S1651P, 14 S1651F, T1691I, V1736A, E1735K, H1746Q and R1753T. T1691I and E1735K were 15 classified as functionally impaired in only one cisplatin sensitivity test, while values from 16 repeat experiments could not be taken into account because of RSE values above 0.1. 17 S4F, S1651P, S1651F, V1736A, H1746Q, and R1753T were differently classified in repeat 18 experiments, which may reflect technical flaws or intermediate activity of these variants. Of 19 note, the V1736A mutation was recently identified as a pathogenic variant with 20 hypomorphic activity in DNA repair (31). While we did not measure significant HR activity 21 of V1736A in a DR-GFP gene conversion assay, intermediate activity of this variant is 22 supported by the results of the proliferation assays and additional cisplatin sensitivity 23 assays. S1651F showed HR activity similar to wild-type BRCA1, whereas R1753T was 24 HR-deficient. S308A is an artificial mutation of a BRCA1 phosphorylation site that was able 25
Research. to support proliferation and resistance to DNA damage in an ES cell-based BAC 1 complementation assay. However, S308A complemented ES cells did show increased 2 apoptosis when cultured in embryoid bodies (7), indicating a partial defect that might 3 explain the ambivalent results for this mutation in our assays. 4
5
Our results show that BRCA1 variants should ideally be assayed in triplicate to avoid 6 misclassification. This also applies to BRCA1 VUS that we classified as neutral, most of 7 which were tested only once because in our current study we focused on variants that 8 showed functional impairment. The striking restriction of unambiguously predicted 9 pathogenic mutants to the terminal RING and BRCT domains suggest that some plasticity 10 is allowed for the central domain of BRCA1. However, our dataset is still limited and more 11 experiments are required to gain insight in the function of this domain. 12
13
Our cDNA-based system allows for several additional functional assays that have been 14 described previously for BAC transgenic ES cells (7) . These include assays for defects 15 during in vitro and in vivo ES cell differentiation but also treatments with other cytotoxic 16 agents. As a proof of principle, we investigated the activity of a number of mutants in the 17 response to the PARP inhibitor olaparib. These included M1400V, L1407 and M1411T, 18 which were previously shown to impair PALB2 binding and have a negative effect on 19 BRCA1 function (10) . While the differences in sensitivity of BRCA1-deficient versus 20 BRCA1-proficient ES cells are larger for olaparib than for cisplatin, increased variation 21 between repeat experiments only allowed us to identify functional defects for L1407 and 22 not for the other two variants in the PALB2 interaction domain, M1400V and M1411T. 23
However, the R1699Q and V1736A variants, which are known to have hypomorphic 24 activity, clearly showed a defect in the response to olaparib. Interestingly, both mutations 25
Research. Platinum drugs and PARP inhibitors are selectively toxic to BRCA1-deficient cells because 6 they target HR deficiency. Although the role of BRCA1 in HR is thought to be essential for 7 maintaining genomic integrity and preventing accumulation of (oncogenic) mutations, other 8 activities may also contribute to its tumor suppression function. These activities may 9 include the HR independent role for BRCA1 in ICL repair, which has been attributed to the 10 facilitation of FANCD2 accumulation at cross-linked DNA (16). Nevertheless, we observed 11 a good correlation between the results of the cisplatin sensitivity assay and the results of 12 the DR-GFP HR assay. All BRCA1 variants that failed to restore the cisplatin response in 13
Brca1-null ES cells were also defective in catalyzing gene conversion, thereby confirming 14 our functional classification. It will be interesting to see if this holds true for all BRCA1 15 variants or whether there are also pathogenic mutations that have no effect on HR. 
factors affect splicing and these may be tissue specific (42). A possible solution would be 1 to determine the presence of BRCA1 splice variants in tumor tissue from BRCA1 VUS 2 carriers and use this information to generate a cDNA construct for analysis of the 3
characterization of large numbers of BRCA1 VUS within the context of the full-length 10 protein. It is our hope that our assay system will find its way to clinical genetics 11 laboratories where it can be used to aid genetic counseling. Ideally, these tests should be 12 
Materials and Methods 1 2
Generation of RMCE vectors containing human BRCA1 sequence variants 3
Human BRCA1 cDNA from a pCDNA3-BRCA1 expression construct (45) was subcloned 4 into the pRNA 251-MCS RMCE exchange vector under control of the EF1A gene 5 promoter. BRCA1 mutations were introduced by site-directed mutagenesis using the 6 QuickChange Lightning protocol (Stratagene) and constructs were verified by sequencing 7 the entire human BRCA1 cDNA (see Supplementary Methods). 8 9
Generation of human BRCA1 transgenic ES cells 10
R26
CreERT2/wt
;Brca1
SCo/ǻ ES cells were generated by gene targeting in 129/Ola E14 IB10 11
ES cells (46). The presence of correctly targeted alleles was verified using Southern 12
blotting, western blotting and PCR analysis (5, 47 
Cytotoxicity and proliferation assays 1
Cre-mediated inactivation of the endogenous mouse Brca1
SCo allele was achieved by 2 overnight incubation of cells with 0.5 ȝM 4OHT (Sigma). One week after switching, cells 3 were seeded in triplicate at 1000 cells/well in 96-well plates for cisplatin or olaparib 4 (AZD2281) sensitivity assays essentially as described (5) . In addition, cells were seeded in 5 triplicate at 500 cells/well on 96-well plates to monitor proliferation. 6 7
HR reporter assays 8
For DR-GFP assays we used a modified version of the p59X DR-GFP construct (12) 9 (kindly provided by T. Ludwig), in which the puromycin resistance marker was inactivated 10 by inversion of an internal SalI fragment. To allow selection of targeted integration of this 11 construct to the Pim1 locus, we equipped the wild-type Rosa26 allele of 12
R26
;Brca1
SCo/ǻ ES cells with Frt and F3 sites for RMCE using a targeting vector in 13 which zsgreen, the hygromycin resistance marker and Flpe were replaced by a puromycin 14 resistance marker. Subsequently, the DR-GFP construct was targeted to the Pim1 locus, 15 BRCA1 variants were introduced using RMCE as described, and cells were subcloned to 16 allow HR reporter assays. HR reporter assays were performed by Lipofectamine 2000 17 transfections of an I-SceI-mCherry plasmid, which was generated by cloning CMV- control, constrained between 1 and 0 using the drc package in the R programming 1 language. We discarded fits that exceeded a 0.1 RSE. To allow comparison between 2 plates we normalized using a linear model based on the positive and negative controls, 3 resulting in corrected IC 50 scores. We estimated normal distributions of the corrected IC 50 4 score for both the pooled positive and negative controls across plates. We used these 5 estimated normals to calculate the probability of pathogenicity for each VUS. 6
Statistical significance for the HR and cytotoxicity assays on selected groups of variants 7 was calculated by two-tailed Student's t test using Prism 6 Software. Significant 8 differences are indicated by *p<0.05, **p<0.01, and *** p<0.001, ****P<0.0001. NS stands 9
for non-significant (p>0.05). 10
11
Computational analysis 12
Alamut software was used to obtain genomic annotations and Align GVGD scores (Human 13 to Sea urchin) for all variants. 
